Lenalidomide (CC-5013) |
| Katalog-Nr.GC14976 |
An analog of thalidomide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 191732-72-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. According to recent studies, Lnalidomide promotes and restores immune system function in CLL patients by inducing an overexpression of costimulatory molecules in leukemic lymphocytes to restore the humoral immunity and immunoglobulins production as well as improving the ability of T cells and leukemic cells to form synapses with T lymphocytes.
Reference
[1].Ana Pilar Gonzalez-Rodriguez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Hergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garcia, and Segundo Gonzalez. Lenalidomide and chronic lymphocytic leukemia. BioMed Research International 2013.
| Cell experiment: [1] | |
|
Cell lines |
Peripheral blood mononuclear cells (PBMCs) |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
10 μM, 7 days |
|
Applications |
The cells were incubated with the dye at 37°C for 10 min and treated for 7 days in RPMI culture medium with lenalidomide. Cells were surface stained with anti-CD4-PerCP and anti-CD25-APC, followed by intracellular staining with anti-FOXP3-PE. Lenalidomide inhibited the expression of CD4+CD25high CTLA-4+FOXP3+ cells. Incubation with lenalidomide significantly decreases expression of the T regulatory cell population after 7 days of culture. The drug decreased the percentage of CD4+CD25high cells expressing both CTLA-4 and FOXP3 from 25 to 12%. |
| Animal experiment: [2] | |
|
Animal models |
Male Sprague–Dawley rats |
|
Dosage form |
Oral administration, 50 mg/kg or 250 mg/kg |
|
Applications |
In the rat mesenteric window assay (RMWA), representative differences between vehicle and 50 or 250 mg/kg lenalidomide-treated rats were visualized by staining with an antibody against rat endothelium in bFGF-induced angiogenic windows. The induction of angiogenesis by bFGF was significantly inhibited by oral treatment of lenalidomide in a dose-dependent manner. Lenalidomide significantly decreased the percentage of vascularized area from 5.16% in the control group to 2.58 and 1.69 in the 50 and 250 mg/kg group, respectively. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Galustian C, Meyer B, Labarthe M C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy, 2009, 58(7): 1033-1045. [2] Dredge K, Horsfall R, Robinson S P, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular research, 2005, 69(1): 56-63. |
|
| Cas No. | 191732-72-6 | SDF | |
| Chemical Name | 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione | ||
| Canonical SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N | ||
| Formula | C13H13N3O3 | M.Wt | 259.3 |
| Löslichkeit | ≥ 100.8 mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8565 mL | 19.2827 mL | 38.5654 mL |
| 5 mM | 0.7713 mL | 3.8565 mL | 7.7131 mL |
| 10 mM | 0.3857 mL | 1.9283 mL | 3.8565 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *